SCHEMBL2416615

SCHEMBL2416615

COc1ccc(COc2nc(I)ccc2OC(C)C)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 6/20 0.48
CNR2 P34972 3/20 0.41
CNR1 P21554 2/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
BCHE P06276 1/20 0.41
MAOB P27338 1/20 0.40
HRH4 Q9H3N8 1/20 0.39
IDO1 P14902 1/20 0.38
AGXT P21549 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
CSF1R P07333 2/20 0.38
NTRK1 P04629 1/20 0.38
NTRK3 Q16288 1/20 0.38
NTRK2 Q16620 1/20 0.38
PDE2A O00408 1/20 0.38
POLB P06746 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ABCB1 P08183 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2418124 0.88 APP (0.47) APPCNR2CNR1NPC1RAB9A
SCHEMBL2414177 0.87 APP (0.54) APPCNR2CNR1NPC1RAB9A
SCHEMBL2433879 0.82 ABCB1 (0.53) APPCNR2CNR1NPC1RAB9A
SCHEMBL2413783 0.81 APP (0.54) APPCNR2CNR1NPC1RAB9A
SCHEMBL2409162 0.81 APP (0.48) APPCNR2CNR1NPC1RAB9A
SCHEMBL23167115 0.81 APP (0.50) APPCNR2CNR1NPC1RAB9A
SCHEMBL14478707 0.79 APP (0.54) APPCNR2CNR1NPC1RAB9A
SCHEMBL12284212 0.77 APP (0.53) APPCNR2CNR1NPC1RAB9A
SCHEMBL23167073 0.74 APP (0.53) APPNPC1RAB9AMAOBIDO1
SCHEMBL2415179 0.74 APP (0.53) APPNPC1RAB9AMAOBIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822503-B2 2-pyridone compounds TAISHO PHARMACEUTICAL CO., LTD (JP) 2014-09-02 US disclosed
US-8822503-B2 2-pyridone compounds TAISHO PHARMACEUTICAL CO., LTD (JP) 2014-09-02 US disclosed
US-8822503-B2 2-pyridone compounds TAISHO PHARMACEUTICAL CO., LTD (JP) 2014-09-02 US disclosed
EP-2508513-A1 2-PYRIDONE COMPOUNDS Taisho Pharmaceutical Co., Ltd. (JP) 2012-10-10 EP disclosed
EP-2508513-A1 2-PYRIDONE COMPOUNDS Taisho Pharmaceutical Co., Ltd. (JP) 2012-10-10 EP disclosed
US-20110237791-A1 2-PYRIDONE COMPOUNDS TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-09-29 US disclosed
US-20110237791-A1 2-PYRIDONE COMPOUNDS TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-09-29 US disclosed
US-20110237791-A1 2-PYRIDONE COMPOUNDS TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-09-29 US disclosed
WO-2011068211-A1 2-PYRIDONE COMPOUNDS 大正製薬株式会社 (JP) 2011-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237791-A1 2-PYRIDONE COMPOUNDS PDXK, HK1, KCNJ2 APP 2520/4885CNR2 825/4885CNR1 985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.